Showing results (511-520 of 541) with videos related to

Sort By:
Pageof 55
Liver Cancer|February 2, 2026
Utility of Biomarker Panels in the Surveillance and Monitoring of Hepatocellular Carcinoma: Consensus Statements from an International Delphi PanelAmit G Singal, Hidenori Toyoda, Tawesak Tanwandee, et al.
Liver Cancer|January 29, 2026
Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective StudyKo Hashimoto, Tomokazu Kawaoka, Tomoaki Emori, et al.
Liver Cancer|December 17, 2024
Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with CirrhosisAmit G Singal, Jagpreet Chhatwal, Neehar Parikh, et al.
Liver Cancer|December 17, 2024
Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-AnalysisYoung-Gi Song, Kyeong-Min Yeom, Eun Ae Jung, et al.
Liver Cancer|December 17, 2024
LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis BSungeun Park, Boyeon Koo, Boryeong Jeong, et al.
Liver Cancer|January 9, 2025
Erratum
Liver Cancer|February 12, 2024
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and ManagementLiangtao Ye, Julia S Schneider, Najib Ben Khaled, et al.
Liver Cancer|February 12, 2024
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L TrialMasatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer|March 13, 2024
Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-AnalysisYizhou Zhang, Minghao Wang, Qichen Chen, et al.
Liver Cancer|October 30, 2023
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 StudyMasatoshi Kudo, Richard S Finn, Ann-Lii Cheng, et al.
Pageof 55